Literature DB >> 8621694

Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing.

M Sowden1, J K Hamm, H C Smith.   

Abstract

Apolipoprotein B (apoB) RNA editing involves site-specific deamination of a cytidine to a uridine. A mooring sequence, a spacer region, and a regulator region are components of the apoB RNA editing motif of which only the mooring sequence is both necessary and sufficient for editosome assembly and editing. The catalytic component of the editosome is APOBEC-1. In rat hepatoma, stable cell lines, overexpression of APOBEC-1 resulted in 3 6-fold stimulation of the editing efficiency on either rat endogenous apoB RNA or transiently expressed human apoB RNA. In these cell lines, cytidines in addition to the one at the wild type site were edited. The occurrence and efficiency of this "promiscuous" editing increased with increasing expression of APOBEC-1. Promiscuous editing was restricted to cytidines 5' of the mooring sequence and only occurred on RNAs that had been edited at the wild type site. Moreover, RNAs with mutant editing motifs supported high efficiency but low fidelity editing in the presence of high levels of APOBEC-1. This study demonstrates that overexpression of APOBEC-1 can increase the efficiency of site-specific editing but can also result in promiscuous editing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621694     DOI: 10.1074/jbc.271.6.3011

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Gene regulation by mRNA editing.

Authors:  J Ashkenas
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

2.  Disruption of a gene encoding a novel mitochondrial DEAD-box protein in Trypanosoma brucei affects edited mRNAs.

Authors:  A Missel; A E Souza; G Nörskau; H U Göringer
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Hypermutation induced by APOBEC-1 overexpression can be eliminated.

Authors:  Zhigang Chen; Thomas L Eggerman; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Gyorgy Csako; Amy P Patterson
Journal:  RNA       Date:  2010-03-26       Impact factor: 4.942

4.  Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing.

Authors:  Y Yang; Y Yang; H C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.

Authors:  Debnath Mukhopadhyay; Shrikant Anant; Robert M Lee; Susan Kennedy; David Viskochil; Nicholas O Davidson
Journal:  Am J Hum Genet       Date:  2001-11-27       Impact factor: 11.025

6.  APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic.

Authors:  Ryan P Bennett; Elie Diner; Mark P Sowden; Joshua A Lees; Joseph E Wedekind; Harold C Smith
Journal:  Biochem Biophys Res Commun       Date:  2006-09-18       Impact factor: 3.575

7.  Structural and functional assessment of APOBEC3G macromolecular complexes.

Authors:  Bogdan Polevoda; William M McDougall; Ryan P Bennett; Jason D Salter; Harold C Smith
Journal:  Methods       Date:  2016-03-14       Impact factor: 3.608

8.  Intestine-specific expression of Apobec-1 rescues apolipoprotein B RNA editing and alters chylomicron production in Apobec1 -/- mice.

Authors:  Valerie Blanc; Yan Xie; Jianyang Luo; Susan Kennedy; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2012-09-19       Impact factor: 5.922

Review 9.  APOBEC-1-mediated RNA editing.

Authors:  Valerie Blanc; Nicholas O Davidson
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Sep-Oct

10.  The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1.

Authors:  Kefang Xie; Mark P Sowden; Geoffrey S C Dance; Andrew T Torelli; Harold C Smith; Joseph E Wedekind
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.